Showing 1-10 of 290 results for "".
Dr. Chan Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-chan-discusses-experience-with-gemini-laser/19471/“Gemini is an extremely effective non-ablative skin rejuvenation laser. And by combining the 532 KTP lasers with the long pulse 1064 YAG, we can achieve non-ablative skin rejuvenations in terms of reductions of pigmentations, fine lines, pore size and vessel improvement.” & #8212Professor HenryActive Vitiligo: What to Look For
https://practicaldermatology.com/series/updates-vitiligo/active-vitiligo-what-to-look-for/24156/John E. Harris, MD, founding director of the Autoimmune Therapeutics Institute at the University of Massachusetts Chan Medical School, talks with Practical Dermatology Chief Medical Editor Neal Bhatia, MD, about the clinical signs of active vitiligo.The Time is Now: Dermatology and Climate Change
https://practicaldermatology.com/topics/practice-management/the-time-is-now-dermatology-and-climate-change/19930/How are global warming and associated changes in weather affecting the presentation of skin diseases? And what opportunities do dermatologists have to help turn the tide of global warning? Misha Rosenbach, MD reviews the science and touches on opportunities for change.Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.Valeant Acquires Salix; Actavis Changing Name
https://practicaldermatology.com/series/dermwire-tv/valeant-acquires-salix-actavis-changing-name/18963/Valeant expands its portfolio with the acquisition of GI market leader Salix. Actavis divests Doryx and considers a name change to Allergan. Kythera acquires rights for investigational hair therapies. And Cynosure's 532nm laser delivery system is FDA cleared for PicoSure.Currents: Win the Adherence Game: Don't Leave Patient Outcomes to Chance
https://practicaldermatology.com/topics/practice-management/win-the-adherence-game/20538/Don't leave patient outcomes to chanceDermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates
https://practicaldermatology.com/topics/psoriasis/dermwiretv-climate-change-and-skin-wynzora-tremfya-rinvoq-updates/19834/The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of DermThe Changing SEO Paradigm for Your Dermatology Website
https://practicaldermatology.com/topics/practice-management/the-changing-seo-paradigm-for-your-dermatology-website/22927/The SEO approach to marketing is rapidly undergoing a paradigm shift. Are you geared up for the change?Positive Changes in My Practice
https://practicaldermatology.com/topics/practice-management/positive-changes-in-my-practice/19044/Sometimes relatively simple changes can have a big impact on a practice. Steve Yoelin, MD talks about positive changes he has made in his practice.DermWireTV: Novan EPI Acquisition, Champions for Change Gala, Mt. Sinai Alopecia Center
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-novan-epi-acquisition-champions-for-change-gala-mt-sinai-alopecia-center/20070/EPI Health is now a Novan company; the combined company will employ approximately 100 staff. Novan’s lead candidate, berdazimer gel 10.3%, performed well in a phase 3 study for the treatment of molluscum contagiosum. The Skin Cancer Foundation is gearing up for its signature fundraising event: The C
- Prev
- Next